Skip to main content

Advertisement

Table 1 Patient characteristics and summary of treatment efficacy

From: Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer

Variable Level N = 20 %
Gender F 7 35.0
M 13 65.0
Race White 16 80.0
Black 4 20.0
Age (years) Mean 63.40 (10.67)  
  Median 63 (48–84)  
Age (years) <65 10 50.0
≥65 10 50.0
ECOG performance status 0 2 10
1 13 65
2 5 25
No of prior therapies 1a 6 30
2b 6 30
3c 7 35
4d 1 5
Best response PD 15 88.2
SD 2 11.8
Time to progression (TTP) Mean 6.26 (3.9)  
Median 7 (1–17)  
  1. aPlatinum/etoposide; platinum etoposide/XRT, platinum/etoposide/GDC-049
  2. bTopotecan, oral etoposide, platinum/irinotecan, platinum/etoposide, topotecan/aflibercept; gemcitabine, paclitaxel
  3. cPlatinum etoposide, platinum/irinotecan, topotecan, irinotecan
  4. dIrinotecan